Navigation Links
TREVENTIS Corporation Scientific Founder, Donald Weaver, MD, Named Sobey Chair in Alzheimer's Disease Research, His Third Endowed Chair

PHILADELPHIA, July 10, 2012 /PRNewswire/ -- TREVENTIS Corporation announced today that the Company's scientific founder, Donald F. Weaver, MD, PhD, was named as the Sobey Chair in Alzheimer's disease research at Dalhousie University in Halifax, Nova Scotia, Canada.  This is the third endowed chair to be held by Dr. Weaver at Dalhousie.  This chair has been established as the result of a $2 million donation to the Dalhousie Medical Research Foundation (DMRF) from the Sobey Foundation.  It will fund the DMRF Irene MacDonald Sobey Endowed Chair in Curative Approaches to Alzheimer's Disease.  The Sobey Foundation is funded by the Sobey family, who operate many diverse companies throughout Canada including chain grocery and drug stores.

Dr. Weaver, a pioneer in the field of computer-aided drug development, is on the trail of an Alzheimer cure.  Dr. Weaver's group uses state-of-the-art computer-aided modeling to develop drugs to prevent and/or slow the progression of Alzheimer's disease.  When certain proteins in the brain aggregate into clumps or tangles, that process is toxic to the brain, killing brain cells and leading to the symptoms of Alzheimer's dementia.  Using computer models, Dr. Weaver is developing drugs that bind to multiple misfolding proteins in the brain, preventing them from aggregating and, thus, halting the brain damage associated with Alzheimer's disease.

The Sobey Chair in Alzheimer's will provide stable annual funding to assist Dr. Weaver and his team in their continued development of lead compounds as potential curative agents for the treatment of Alzheimer's disease.  Dr. Weaver assigns these compounds for commercialization to TREVENTIS Corporation, a company that he helped found.

"We congratulate Don on this most prestigious appointment that serves to support his over- 20-year's work to discover a cure for dementias such as Alzheimer's," said Bill McIntosh, Chairman and CEO of TREVENTIS.  "The Company is pleased to work toward the ultimate commercialization of his discoveries."

About TREVENTIS Corporation 

TREVENTIS is headquartered in Southeastern Pennsylvania and has research operations in Halifax, Nova Scotia, Canada.  The Company is focused on the discovery and early stage development of disease-modifying small molecule drugs for a variety of dementias including Alzheimer's.  In addition to its therapeutic programs, TREVENTIS has a novel approach to the development of diagnostics for early diagnosis and monitoring of treatment effects in Alzheimer's disease.  

Contact: L. William McIntosh

TREVENTIS, Chairman and CEO

Phone: 610-488-6081

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
2. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
3. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
4. Neogen Corporation Announces 2nd Quarter Results Conference Call
5. Luminex Corporation to Present at JP Morgan Healthcare Conference
6. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
7. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
8. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
9. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
10. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
11. Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
Post Your Comments:
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
Breaking Biology News(10 mins):